. Author manuscript; available in PMC: 2017 Aug 1.

Published in final edited form as: BJU Int. 2015 Dec 13;118(2):264–271. doi: 10.1111/bju.13374

Table 4. Overall Survival (OS) for Second-Line Therapy Following First-Line Pazopanib.

Second Line Therapy	Number of patients	Median (95% CI)	OS Rate at 1 Year (95% CI)	OS Rate at 2 Years (95% CI)	P-value (Median OS VEGFR-TKI vs mTORi)
VEGFR-TKI	22 - (17 sunitinib/ 2 sorafenib/ 3 axitinib)	19.9 months (95% CI: 12.9 - NA )	0.76 (95% CI: 0.6 - 0.97 )	0.45 (95% CI: 0.27 - 0.77)	0.37
mTOR inhibitor	22 - (17 everolimus/ 5 temsirolimus)	14.2 months (95% CI: 8.1 - NA )	0.5 (95% CI: 0.32 - 0.78 )	0.19 (95% CI: 0.04 - 0.89 )